



Radiation Efficacy and Safety

Services deliver efficacy and safety evaluation to advance product development for radiation protection, decorporation, and therapy

SRI International is a renowned expert in:

- Mechanisms of radiation injury and recovery;
- Efficacy of modifiers to radiation effects in the area of protection against normal tissue injury; and
- Sensitizers in radiotherapy.

SRI Biosciences[™] offers services to evaluate promising candidates that are effective in protecting individuals from the consequences of unexpected external radiological exposure or in serving as decorporation agents for internalized radionuclides.

Studies provided include efficacy and safety of small molecules and biologics for advancing new therapies or repurposing approved products.

In projects of a highly experimental nature, we work closely with business clients, government agencies, and other partners to design and execute studies that will give the highest return on investment.

SRI offers expertise at every step in product development with high level administrative and technical support provided throughout each project.

Our preclinical experts provide:

Efficacy

- In vitro and in vivo screening studies
- In vivo model development
- Pilot and pivotal efficacy testing
- Non-invasive imaging for late radiation effects
- Nonclinical GLP safety studies
- Chemistry manufacturing & control services
- Clinical support services

GLP-Compliant Safety Evaluation

 Individual studies and comprehensive drug development programs

Irradiation Facilities

- Pantak X-ray 320 kVp system
- Mark 1-68A Cs-137 gamma emission source
- Other studies with partners
- Veterinary facilities and care are AAALAC accredited, IACUC approved, and fully GLP-compliant

Selected References

D. Bunin, J. Bakke, C.E. Green, H.S. Javitz, M. Fielden, P.Y. Chang. Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice. International Journal of Radiation Biology, 2019 Epub April 25, doi: 10.1080/09553002.2019.1605465. [Epub ahead of print]

K. Wong, P. Chang, M. Fielden, A.M. Downey, D. Bunin,
J. Bakke, J. Gahagen, L. Iyer, S. Doshi, W. Wierzbicki,
S. Authier. Pharmacodynamics of Romiplastim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in nonhuman primates. International Journal of Radiation Biology, 2019, in press.
[Epub ahead of print]

P.Y. Chang, F.A. Cucinotta, K.A. Bjornstad, J. Bakke, C.J. Rosen, N. Du, D.G. Fairchild, E. Cacao, E.A. Blakely. Harderian Gland Tumorigenesis: Low-Dose and LET Response. Radiation Research, 185, 449 – 460 (2016).

P. Y. Chang, J. Roelands, J. Schindler-Horvat, and R.L. Sheets, Chapter 14: Toxicity Testing of Vaccines, in Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registrations. Edited by William Sietsema and Rick Schwen. Publisher: FDAnews, Washington, DC, (2007).

From Idea to IND and Beyond[™]

SRI Biosciences is a well-established, trusted source for a wide array of contract services under the highest industry standards. With deep scientific resources and expertise, we take R&D from idea to discovery through the start of human clinical trials. SRI Biosciences specializes in cancer, immunology and inflammation, infectious disease, and neuroscience.

U.S. National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) support: Contract No.: HHSN2722015000131

Title: Radiation/Nuclear Medical Countermeasure (MCM) Product Development Support Services

SRI Biosciences

SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. SRI International, a research center headquartered in Menlo Park, California, creates world-changing solutions to make people safer, healthier, and more productive.



SRI International and Iris on the Move are registered trademarks of SRI International. All other trademarks are the property of their respective owners. Copyright 2019 SRI International. All rights reserved. 10/2019

Silicon Valley

(Headquarters) 333 Ravenswood Avenue Menlo Park, CA 94025 Email: biosciences@sri.com Phone: +1.650.859.3000 Toll Free: +1.866.451.5998

www.sri.com/biosciences